Skip to main content
. Author manuscript; available in PMC: 2019 Apr 4.
Published in final edited form as: Pharmacotherapy. 2018 Jul 26;38(9):907–920. doi: 10.1002/phar.2158

Figure 6.

Figure 6.

Quarterly trends in oral anticoagulant prescriptions for atrial fibrillation for cardiologists and primary care physicians, from the fourth quarter of 2010 (2010Q4) to the first quarter of 2017 (2017Q1)

Y-axis refers to the percentage of incident OAC users prescribed a specific OAC.

OAC indicates oral anticoagulant; NOAC, non-vitamin K antagonist oral anticoagulant, including dabigatran, rivaroxaban, and apixaban.